DOI: https://doi.org/10.18370/2309-4117.2019.46.%p

Modern approaches to diagnostics of hyperandrogenism distributed forms in reproductive aged women

О. А. Бурка, Т. М. Тутченко

Abstract


Hyperandrogenism (HA) is characterized by elevated levels of circulating androgens and/or the presence of clinical manifestations their biological effects. HA incidence in the female population is around 8%. Causes of HA vary widely and its pathogenesis is not always completely clear. HA in women has a negative effect on fertility and metabolism. HA origins are divided into true adrenal or ovarian; peripheral/receptor; iatrogenic; transport and secondary.

HA accompanies a fairly wide range of diseases and conditions. Most diseases are accompanied by mixed forms of HA, when there is a primary source and additional or secondary. The contribution of various HA sources in mixed forms may vary over time and depending on the exogenous or endogenous factors impact. Often an important HA component is free testosterone form predominance due to the reduced synthesis of sex hormone-binding globulin. All this dictates the need for a differentiated approach to the laboratory HA diagnosis for various diseases, especially fertility disorders.

Such wide spread hyperandrogenic condition as PCOS not only affect female fertility but are also associated with increased life-long metabolic risks. Today it is recommended to use the following PCOS criteria: a combination of at least two of the three criteria: oligo/anovulation; polycystic ovarian morphotype; clinical or biochemical HA.

Laboratory diagnosis of PCOS includes: tests to exclude other causes of HA and oligo/anovulation (differential diagnosis of PCOS), tests to confirm the diagnosis of PCOS according to criteria (biochemical HA evaluation), additional tests to diagnose PCOS, especially of normoandrogenic phenotypes forms; tests to diagnose the metabolic complications of PCOS.


Keywords


hyperandrogenism; free testosterone; bioavailable testosterone; polycystic ovary syndrome; anti-Mullerian hormone; phenotypic forms of polycystic ovary syndrome

References


Practice Committee of the American Society for Reproductive Medicine. ”The evaluation and treatment of androgen excess.” Fertil Steril 86.5 (2006): S241–7.

Lizneva, D., Gavrilova-Jordan, L., Walker, W., Azziz, R. ”Androgen excess: Investigations and management.” Best Pract Res Clin Obstet Gynaecol 37 (2016): 98–118.

Burger, H.G. ”Androgen production in women.” Fertil Steril 77 (2002): 3–5.

Yang, R., Yang, S., Li, R., et al. ”Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: a meta-analysis.” Reprod Biol Endocrinol 14.1 (2016): 67.

Enea, C., Boisseau, N., Fargeas-Gluck, M.A., et al. ”Circulating Androgens in Women.” Sport Med 41.1 (2011) :1–15.

Botwood, N., Hamilton-Fairley, D., Kiddy, D., et al. ”Sex hormone-binding globulin and female reproductive function.” J Steroid Biochem Mol Biol 53.1–6 (1995): 529–31.

Abu-Hijleh, T.M., Gammoh, E., Al-Busaidi, A.S., et al. ”Common Variants in the Sex Hormone-Binding Globulin (SHBG) Gene Influence SHBG Levels in Women with Polycystic Ovary Syndrome.” Ann Nutr Metab 68.1 (2016): 66–74.

Walters, K.A., Gilchrist, R.B., Ledger, W.L., et al. ”New Perspectives on the Pathogenesis of PCOS: Neuroendocrine Origins.” Trends Endocrinol Metab 29.12 (2018): 841–52.

Crespo, R.P., Bachega, T.A.S.S., Mendonça, B.B., Gomes, L.G. ”An update of genetic basis of PCOS pathogenesis.” Arch Endocrinol Metab 62.3 (2018): 352–61.

Baptiste, C., Battista, M., et al. ”AT-TJ of steroid, 2010 undefined. Insulin and hyperandrogenism in women with polycystic ovary syndrome.” Elsevier 122.1–3 (2010): 42–52.

Barber, T.M., Joharatnam, J., Franks, S. ”Pathogenesis and Management of Adiposity and Insulin Resistance in Polycystic Ovary Syndrome (PCOS).” In: Pediatric Obesity. Cham. Springer International Publishing (2018): 629–42.

Diamanti-Kandarakis, E., Dunaif, A. ”Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications.” Endocr Rev 33.6 (2012): 981–1030.

Witchel, S.F., Azziz, R. ”Nonclassic Congenital Adrenal Hyperplasia.” Int J Pediatr Endocrinol 1 2010: 1–11.

Speiser, P.W., Arlt, W., Auchus, R.J., et al. ”Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 103.11 (2018): 4043–88.

Cordera, F., Grant, C., van Heerden, J., et al. ”Androgen-secreting adrenal tumors.” Surgery 134.6 (2003): 874–80.

Lobo, R.A. ”Ovarian hyperandrogenism and androgen-producing tumors.” Endocrinol Metab Clin North Am 20.4 (1991): 773–805.

Brown, D.L., Henrichsen, T.L., Clayton, A.C., et al. ”Ovarian Stromal Hyperthecosis.” J Ultrasound Med 28.5 (2009): 587–93.

Sánchez, P., Serrano-Falcón, C., Torres, J.M., et al. ”5α-Reductase isozymes and aromatase mRNA levels in plucked hair from young women with female pattern hair loss.” Arch Dermatol Res 310.1 (2018): 77–83.

Bienenfeld, A., Azarchi, S., Lo Sicco, K., et al. ”Androgens in Women: Androgen mediated skin disease and patient evaluation (Part I).” J Am Acad Dermatol (2018). DOI: 10.1016/j.jaad.2018.08.062

Hagag, P., Hertzianu, I., Ben-Shlomo, A., Weiss, M. ”Androgen suppression and clinical improvement with dopamine agonists in hyperandrogenic-hyperprolactinemic women.” J Reprod Med 46.7 (2001): 678–84.

Vyakaranam, S., Vanaparthy, S., Nori, S., et al. ”Study of Insulin Resistance in Subclinical Hypothyroidism.” Int J Heal Sci Res 4.9 (2014): 147–53.

Auriemma, R.S., Granieri, L., Galdiero, M., et al. ”Effect of Cabergoline on Metabolism in Prolactinomas.” Neuroendocrinology 98.4 (2013): 299–310.

Daimon, M., Kamba, A., Murakami, H., et al. ”Association between serum prolactin levels and insulin resistance in non-diabetic men.” PLoS One 12.4 (2017): e0175204.

Rachoń, D. ”Differential Diagnosis of Hyperandrogenism in Women with Polycystic Ovary Syndrome.” Exp Clin Endocrinol Diabetes 120.04 (2012): 205–9. DOI:10.1055/s-0031-1299765

Pivonello, R., Isidori, A.M., De Martino, M.C., et al. ”Complications of Cushing’s syndrome: state of the art.” Lancet Diabetes Endocrinol 4.7 (2016): 611–29.

Melmed, S. ”Acromegaly.” In: Pituitary (Forth edition). Academic Press (2017): 423–66.

Varlamov, O., Bethea, C.L., Roberts, C.T. ”Sex-Specific Differences in Lipid and Glucose Metabolism.” Front Endocrinol

(Lausanne) 5 (2015): 241.

Paschou, S.A., Anagnostis, P., Goulis, D.G., Lambrinoudaki, I. ”Androgen excess and post-reproductive health.” Maturitas 115 (2018): 115–6.

Herzog, A.G. ”Disorders of reproduction in patients with epilepsy.” Zeitschrift für Epileptol 28.4 (2015): 254–63.

Kumar, A., Woods, K.S., Bartolucci, A.A., Azziz, R. ”Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).» Clin Endocrinol (Oxf) 62.6 (2005): 644–9.

Yildiz, B.O., Azziz, R. ”The adrenal and polycystic ovary syndrome.” Rev Endocr Metab Disord 8.4 (2007): 331–42.

Carmina, E., Azziz, R., Bergfeld, W., et al. ”Female pattern hair loss and androgen excess: a report from the multidisciplinary androgen excess and PCOS Committee.” J Clin Endocrinol Metab (2019). DOI: 10.1210/jc.2018-02548/5342938

Legro, R.S., Arslanian, S.A., Ehrmann, D.A., et al. ”Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 98.12 (2013): 4565–92.

Conway, G., Dewailly, D., Diamanti-Kandarakis, E., et al. ”The polycystic ovary syndrome: a position statement from the European Society of Endocrinology.” Eur J Endocrinol 171.4 (2014): P1–29.

Teede, H.J., Misso, M.L., Costello, M.F., et al. ”Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.” Hum Reprod 33.9 (2018): 1602–18.

Melmed, S., Casanueva, F.F., Hoffman, A.R., et al. ”Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 96.2 (2011) :273–88. DOI: 10.1210/jc.2010-1692

Jonklaas, J., Bianco, A.C., Bauer, A.J., et al. ”Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.” Thyroid 24.12 (2014): 1670–751.

Webber, L., Davies, M., Anderson, R., et al. ”ESHRE Guideline: management of women with premature ovarian insufficiency.” Hum Reprod 31.5 (2016): 926–37.

Gordon, C.M., Ackerman, K.E., Berga, S.L., et al. ”Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 102.5 (2017): 1413–39. DOI: 10.1210/jc.2017-00131

Speiser, P.W., Azziz, R., Baskin, L.S., et al. ”Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 95.9 (2010): 4133–60. DOI: 10.1210/jc.2009-2631

Mihailidis, J., Dermesropian, R., Taxel, P., et al. ”Endocrine evaluation of hirsutism.” Int J Women’s Dermatology 3.1 (2017): S6–10.

Goodarzi, M.O., Carmina, E., Azziz, R. ”DHEA, DHEAS and PCOS.” J Steroid Biochem Mol Biol 145 (2015): 213–25.

Tremellen, K., Zander-Fox, D. ”Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan.” Aust New Zeal J Obstet Gynaecol 55.4 (2015): 384–9. DOI: 10.1111/ajo.12366

Bani Mohammad, M., Majdi Seghinsara, A. ”Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH.” Asian Pac J Cancer Prev 18.1 (2017): 17–21.

Fiçicioǧlu, C., Kutlu, T., Baglam, E., Bakacak, Z. ”Early follicular antimüllerian hormone as an indicator of ovarian reserve.” Fertil Steril 85.3 (2006): 592–6.

Garg, D., Tal, R. ”The role of AMH in the pathophysiology of polycystic ovarian syndrome.” Reprod Biomed Online 33.1 (2016): 15–28.

Sahmay, S., Aydogan Mathyk, B., Sofiyeva, N., et al. ”Serum AMH levels and insulin resistance in women with PCOS.” Eur J Obstet Gynecol Reprod Biol 224 (2018): 159–64.

Lie Fong, S., Laven, J.S.E., Duhamel, A., Dewailly, D. ”Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.” Hum Reprod 32.8 (2017): 1723–31. DOI: 10.1093/humrep/dex226

Sova, H., Unkila-Kallio, L., Tiitinen, A., et al. ”Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes.” Gynecol Endocrinol 1–6 (2019). DOI: 10.1080/09513590.2018.1559807

Mumford, S.L., Legro, R.S., Diamond, M.P., et al. ”Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome.” J Clin Endocrinol Metab 101.9 (2016): 3288–96. DOI: 10.1210/jc.2016-1340

Pfeifer, S., Butts, S., Dumesic, D., et al. ”Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline.” Fertil Steril 106.7 (2016): 1634–47.

Rey, R., Sabourin, J.-C., Venara, M., et al. ”Anti-Müllerian hormone is a specific marker of Sertoli- and granulosa-cell origin in gonadal tumors.” Hum Pathol 31.10 (2000): 1202–8.

Pinola, P., Puukka, K., Piltonen, T.T., et al. ”Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life.” Fertil Steril 107.3 (2017): 788–795.e2.


GOST Style Citations






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)